Biotech · Public company · Cambridge, MA, US
Sarepta Therapeutics, Inc.
Ticker SRPT · SEC CIK 0000873303
Track this companyFree. Adds Sarepta Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2510 recruiting or active
Pipeline programs22From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline22
- CasimersenPhase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- CorticosteroidPhase 3 · Muscular Dystrophies, Limb-GirdleClinicalTrials.gov · fetched Nov 12, 2026
- delandistrogene moxeparvovecPhase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- EteplirsenPhase 3 · Muscular Dystrophy, DuchenneClinicalTrials.gov · fetched Nov 12, 2026
- GlucocorticoidPhase 3 · Limb-girdle Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- GolodirsenPhase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- SRP-4045Phase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- SRP-4053Phase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- SRP-9003Phase 3 · Limb-girdle Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- SRP-9005Phase 3 · Muscular Dystrophies, Limb-GirdleClinicalTrials.gov · fetched Nov 12, 2026
- delandistrogene moxeparvovecPhase 2 · Muscular Dystrophy, DuchenneClinicalTrials.gov · fetched Nov 12, 2026
- SRP-5051Phase 2 · Muscular Dystrophy, DuchenneClinicalTrials.gov · fetched Nov 12, 2026
- SRP-9003Phase 2 · Limb-Girdle Muscular Dystrophy, Type 2EClinicalTrials.gov · fetched Nov 12, 2026
- VesleteplirsenPhase 2 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- PlasmapheresisPhase 1 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- SRP-6004Phase 1 · Limb Girdle Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- SRP-9004Phase 1 · Limb Girdle Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- AntibioticsDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- ELEVIDYSDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- EteplirsenDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- GlucocorticoidsDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- SirolimusDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing SettingPHASE4 · RECRUITING · started Oct 30, 2026ClinicalTrials.gov NCT07542314 · fetched Nov 12, 2026
- A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult ParticipantsPHASE3 · WITHDRAWN · started Jun 30, 2025ClinicalTrials.gov NCT06952686 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United StatesPHASE1 · TERMINATED · started Jan 9, 2025ClinicalTrials.gov NCT06747273 · fetched Nov 12, 2026
- A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74PHASE1 · TERMINATED · started Sep 18, 2024ClinicalTrials.gov NCT06597656 · fetched Nov 12, 2026
- An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular DystrophyENROLLING_BY_INVITATION · started Feb 7, 2024ClinicalTrials.gov NCT06270719 · fetched Nov 12, 2026
- A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 15, 2024ClinicalTrials.gov NCT06246513 · fetched Nov 12, 2026
- A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical StudyPHASE3 · ENROLLING_BY_INVITATION · started Sep 27, 2023ClinicalTrials.gov NCT05967351 · fetched Nov 12, 2026
- A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)PHASE3 · ACTIVE_NOT_RECRUITING · started May 31, 2023ClinicalTrials.gov NCT05881408 · fetched Nov 12, 2026
- A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)PHASE1 · TERMINATED · started May 22, 2023ClinicalTrials.gov NCT05906251 · fetched Nov 12, 2026
- A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)PHASE1 · ACTIVE_NOT_RECRUITING · started Dec 19, 2022ClinicalTrials.gov NCT05876780 · fetched Nov 12, 2026
- A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)PHASE3 · COMPLETED · started Oct 27, 2021ClinicalTrials.gov NCT05096221 · fetched Nov 12, 2026
- A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical PracticeACTIVE_NOT_RECRUITING · started Apr 22, 2021ClinicalTrials.gov NCT04475926 · fetched Nov 12, 2026
- A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory CohortPHASE1 · RECRUITING · started Nov 23, 2020ClinicalTrials.gov NCT04626674 · fetched Nov 12, 2026
- An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular DystrophyPHASE4 · TERMINATED · started Oct 31, 2020ClinicalTrials.gov NCT04708314 · fetched Nov 12, 2026
- A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)PHASE3 · COMPLETED · started Jul 13, 2020ClinicalTrials.gov NCT03992430 · fetched Nov 12, 2026
- A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.PHASE2 · COMPLETED · started Feb 18, 2020ClinicalTrials.gov NCT04179409 · fetched Nov 12, 2026
- Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping TreatmentPHASE2 · TERMINATED · started Jun 26, 2019ClinicalTrials.gov NCT04004065 · fetched Nov 12, 2026
- A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical PracticeENROLLING_BY_INVITATION · started Jan 7, 2019ClinicalTrials.gov NCT06606340 · fetched Nov 12, 2026
- An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)PHASE1_PHASE2 · TERMINATED · started Dec 19, 2018ClinicalTrials.gov NCT03675126 · fetched Nov 12, 2026
- A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)PHASE1_PHASE2 · COMPLETED · started Dec 5, 2018ClinicalTrials.gov NCT03769116 · fetched Nov 12, 2026
- Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)PHASE1_PHASE2 · TERMINATED · started Oct 27, 2018ClinicalTrials.gov NCT03652259 · fetched Nov 12, 2026
- Early Check: Expanded Screening in NewbornsACTIVE_NOT_RECRUITING · started Oct 15, 2018ClinicalTrials.gov NCT03655223 · fetched Nov 12, 2026
- An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyPHASE3 · TERMINATED · started Aug 2, 2018ClinicalTrials.gov NCT03532542 · fetched Nov 12, 2026
- A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)PHASE1_PHASE2 · COMPLETED · started Jan 4, 2018ClinicalTrials.gov NCT03375164 · fetched Nov 12, 2026
- Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)PHASE3 · COMPLETED · started Sep 28, 2016ClinicalTrials.gov NCT02500381 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026